TERN-101

DB16045InvestigationalSmall molecule

TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).

Mechanism: Pharmacologically active on Bile acid receptor
Curator reviewed
Formula / weight: C₂₈H₂₇Cl₂N₃O₄ · 540.44 g/mol (avg)
Code names: LY-2562175 · TERN-101

Resolves to

Compound

UNIIVVA2ZDV3LXCAS1103500-20-4ChEMBLCHEMBL3746388

Structure

InChIKeyRPVDFHPBGBMWID-UHFFFAOYSA-NSMILESCN1C=C(C(O)=O)C2=C1C=C(C=C2)N1CCC(CC1)OCC1=C(ON=C1C1=C(Cl)C=CC=C1Cl)C1CC1

Targets

Q96RI1NR1H4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with TERN-101, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account